TrialBritish journal of cancer2011

Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity.

K-p Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.